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Abstract 
In the recent years, nanoporous silica materials have been regarded as promising nano-
carriers to deliver various therapeutic agents, due to their high pore volume and surface 
area, ease of surface functionalization and excellent biocompatibility. Although numerous 
porous silica nanoparticles have been developed for therapeutic delivery, more efforts are 
still needed in the synthesis of nanoporous silica nanoparticles simultaneously possessing 
good dispersity, high uniformity, small particle size (< 200 nm) for efficient cellular uptake 
and sufficient pore size to encapsulate desired therapeutic agents with large molecular 
sizes. 
 
This thesis focuses on synthesizing self assembled porous silica nanoparticles for high 
performance of biomedical applications. Three types of porous silica nanoparticles, 
including silica vesicles, SBA-15 rods and mesoporous organosilica nanoparticles will be 
synthesized. The self assembly based formation mechanism will be discussed, which is 
believed as a key to design porous silica nanoparticles with superior and more controllable 
structures and properties. In addition, their drug/protein loading capacity and release 
profile, biocompatibility, cellular uptake performance, and therapeutic efficacy will be 
evaluated in vitro.    
 
The first part of the experimental chapters focuses on the synthesis of silica vesicles (SVs) 
with a diameter of 30 nm and reduced aggregation using mixed triblock copolymer 
surfactants as the structure-directing agents, tetraethyl orthosilicate (TEOS) and 
tetrapropyl orthosilicate (TPOS) as mixed silica sources. The reduced aggregation is 
attributed to the incompletely hydrolysed hydrophobic –OCH2CH2CH3 groups of TPOS on 
the surface of SVs, thus preventing the inter-particle aggregation. The drug delivery 
performance of SVs is evaluated using a photosensitizer ─ silicon phthalocyanine 
dichloride (SiPC) as a model drug. The cell viability results show the significantly 
enhanced cell inhibition of SiPC-SV (~61.5%) compared to pure drug (~35.5%). The 
efficient cellular uptake of SiPC-SV is also visualized by confocal image. Those results 
strongly suggest the potential application of the SVs as nanocarriers for efficient cancer 
therapy.  
 
In the second part of the experimental chapters, porous silica nanoparticles with rod like 
morphology are prepared. The sized of SBA-15 rods can be controlled from ~100 nm to ~1 
μm by finely tuning the synthesis pH in a narrow range of 3.40–3.88. The smallest SBA-15 
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rod obtained at pH 3.88 (SR-3.88) is 80-200 nm in length, 18±8 nm in width with a pore 
size of 8.3 nm. Compared to traditional SBA-15 with larger particle sizes and MCM-41 with 
smaller pore sizes, we demonstrate their improved adsorption capacity towards large 
protein molecules such as bovine serum albumin (438 mg g-1) and lysozyme (417 mg g-1). 
The cellular uptake of SR-3.40, SR-3.88 and MCM-41 in human osteosarcoma cancer 
cells is visualized using confocal image and quantified using ICP technique, revealing the 
significantly enhance cellular uptake efficiency of SR-3.88 (7.4 pg/cell) compared to SR-
3.40 (2.0 pg/cell) and MCM-41 (6.1 pg/cell). Hence, the SBA-15 rods with small particle 
sizes, large pores as well as excellent biocompatibility are believed as a promising delivery 
system for cellular delivery of large molecular weight therapeutic agents with improved 
efficacy. 
 
Lastly, we tuned the composition of porous silica nanoparticles by incorporating benzene 
groups in the silica framework to synthesize large pore well dispersed mesoporous 
organosilica nanoparticles (MOSNs) by using a biphase synthesis approach. The role of 
the biphase system has been demonstrated essential to enlarge pore size and facilitate 
the surfanctant/organosilica precursor assembly. The obtained MOSNs with pore size of 
7.6 nm show enhanced protein loading capacity at 144.5 μg mg-1 and sustained release 
profile over 72 hours. In order to investigate the potential in biomedical application, the 
efficient cell uptake is firstly visualized using confocal image and the low cytotoxicity of 
nanopaticles (<25% cell death) were confirmed using MTT assay at 24 h, 48 h and 72 h at 
different concentrations. Furthermore, the protein loaded MOSNs shows significantly 
enhanced cell inhibition of ~64% at 72h, while pure protein show only negligible 
cytotoxicity at the same condition. These results clearly suggested the promising potential 
of large pore MOSNs for efficient intracellular protein delivery applications. 
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Chapter 1. Introduction 
1.1 Background  
Cancer, as a class of diseases characterized by uncontrolled cell growth, has been among 
the leading cause of death worldwide. The key problems of tradition cancer therapy are 
the severe side effects and low therapeutic efficiency due to the nonspecific cellular 
uptake, low bioavailability and poor cell membrane permeability. In the recent years, 
nanotechnology based cancer therapy has shown very promising results and begun an 
evolution from traditional methodology. Owing to the remarkable progress in materials 
synthesis, the fabrication of nanocarriers with diverse size, texture and physical properties 
have been successfully achieved. Typical examples include liposomes, polymer particles, 
single walled carbon nanotubes, silica nanoparticles, gold nanoparticles, et al.. Many 
conventional therapeutic agents have shown significantly improved efficiency with the aid 
of nanocarriers based drug delivery system. Nevertheless, current achievement is still as a 
proof of concept and unsuitable for clinical applications. Basically, the key requirements for 
nanocarriers for efficient delivery are as follows: (1) high loading capacity, (2) controlled 
release of drugs, (3) efficient cellular uptake and (4) high biocompatibility/biodegradability 
to reduce unwanted side effects.1, 2 
 
Since the discovery of MCM-type porous silica nanoparticles in 1990s by Mobile scientist,3 
a new research field regarding porous materials was initiated. Silica based porous 
materials have many advantages compared to conventional organic or inorganic materials, 
including high surface area, controllable morphology and pore structure, ease of surface 
functionalization, excellent biocompatibility, biodegradability and ease of fabrication. In 
recent decades, a variety of methods have been developed to prepare porous silica 
nanoparticles with various particle size, pore size, morphoplogy, composition, et al.. Owing 
to the broad diversity, porous silica nanoparticles based nanoscale systems for therapeutic 
delivery, including drug, protein and gene, have recently attract much attention due to their 
ease of surface functionality and excellent biocompatibility. The need for porous silica 
nanoparticles that efficiently load therapeutic agents and internalized by cells arises 
because therapeutic efficiency is highly related to intracellular dosage of therapeutic 
agents. It is well known that high pore volume and large pore size favour high loading 
capacity of therapeutic agents, in particular for large sized ones, such as proteins and 
genes. In terms of cell internalization, nanoparticles with small particle size (< 200 nm) and 
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good dispersity show superior performance. Hence, synthesis of porous silica 
nanoparticles with high pore volume, large pore size, small particle size and good 
dispersity is highly demanding.  
 
Since the current achievement of nanomaterial based therapeutic delivery system is still 
far away from clinical applications, the need to establish novel porous silica nanocarriers 
with enhanced biomedical suitability and performance underlies the importance of a 
comprehensive study of the nanoparticles fabrication and their application for therapeutic 
delivery. The knowledge gained from this systematic study will be helpful for the design of 
efficient nanocarriers for cellular delivery of various types of therapeutic agents with 
improved therapy efficacy, which will be helpful in development of novel delivery platforms.  
 
1.2 Research objective and scope 
The project aims at synthesizing different type of porous silica nanoparticles via 
cooperative self assembly mechanism. Silica vesicles, SBA-15 rods and mesoporous 
organosilica nanoparticles with small particle size, large pore size, good dispersity and 
tuneable structures will be prepared for effective intracellular drug delivery. In addition, the 
fundamental correlation between the particle structure parameters and therapy efficacy will 
be established based on drug adsorption capacity and cell uptake efficiency. With the 
focus on the development of novel porous silica nanoparticles for therapeutic delivery, the 
objectives to be achieved by this project are specified as follows: 
 
1) Synthesize small sized silica vesicles with reduced aggregation and understand the 
fundamental principle to improve nanoparticle dispersity. After encapsulation of anticancer 
drug, the cancer therapy efficacy will be evaluated. 
2) Synthesize rod like SBA-15 nanoparticles with tuneable particle sizes. The correlation 
between particle size and protein adsorption capacity, as well as cellular uptake efficiency 
will be established. 
3) Synthesize well dispersed benzene bridged mesoporous organosilica nanoparticles with 
tuneable pore size. The influence of pore size on the therapeutic protein adsorption 
capacity, release profile and cell inhibition efficiency will be studied. 
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1.3 Thesis outline 
This thesis is written according to the guidelines of the University of Queensland. 
Outcomes of this MPhil program are presented in the form of journal publications. This 
thesis consists six chapters, which are presented in the following sequence: 
 
Chapter 1. Introduction 
A brief overview of the background of this research is demonstrated, including the 
objectives, significance and scope of the work.  
 
Chapter 2. Literature review 
An overview on nanomaterials that are currently being designed for therapeutic 
applications, with a special focus on silica based nanomaterials. A discussion on existing 
synthetic approaches for porous silica nanoparticles will be provided as well. 
 
Chapter 3. Synthesis of Silica Vesicles with Small Sizes and Reduced Aggregation 
for Photodynamic Therapy 
This chapter reports synthesis of silica vesicles with a diameter of 30 nm and reduced 
aggregation have been successfully synthesized using mixed triblock copolymer 
surfactants as the structure-directing agents, tetraethyl orthosilicate and tetrapropyl 
orthosilicate as mixed silica sources. Silicon phthalocyanine dichloride has been loaded 
into SV, significantly enhancing the delivery and photodynamic therapy efficiency of SiPC 
into cancer cells. 
This chapter was published in Chemistry letters, 2014, 43, 316–318. 
 
Chapter 4. Synthesis of SBA-15 rods with Small Sizes for Enhanced Cellular Uptake 
This chapter reports synthesis of small sized SBA-15 rods with 80–200 nm in length, 18±8 
nm in width and a pore size of 8.3 nm have been successfully synthesized by finely tuning 
the synthesis pH in a narrow range of 3.40–3.88. Compared to traditional SBA-15 with 
relatively larger particle sizes and MCM-41 with smaller pore sizes, SBA-15 rods prepared 
in this study demonstrate higher adsorption capacity towards large protein molecules such 
as bovine serum albumin and lysozyme, and enhanced cellular uptake efficiency in human 
osteosarcoma cancer cells. This novel silica material with small particle sizes, large pores 
as well as excellent biocompatibility is a promising delivery system for the cellular delivery 
of large molecular weight therapeutic agents with improved efficacy. 
This chapter was published in Journal of Materials Chemistry B, 2014, 2, 4929. 
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Chapter 5. Synthesis of Well Dispersed Benzene Bridged Periodic Mesoporous 
Organosilicas with Tuneable Pore Size for Intracellular Protein Delivery  
In this chapter, a facile biphase synthesis approach has been developed to prepare large 
pore (4.6-7.6 nm) well dispersed MOSNs with uniform particle size of ~50 nm. The dual 
roles of the upper oil phase, including swelling mesopores and facilitating 
surfactant/organosilica assembly, are proposed.  With respect to biomedical application, 
MOSNs-7.6 show improved adsorption capacity more sustained release profile of RNase 
A than that of MOSNs-4.6.  The efficient cell uptake performance of MOSNs-7.6 is 
evidenced by CLSM image. RNase A loaded MOSNs-7.6 exhibits significantly enhanced 
cell inhibition compared to pure RNase A at a very low effective dosage of 4 μg ml-1, 
Thus, the large pore MOSNs based protein delivery system is expected as promising 
platform for cellular delivery of various large biomacromolecules. 
 
Chapter 6. Conclusions and recommendations 
This chapter presents conclusions of this thesis and recommendations for the future work. 
 
1.4 References 
1. W. X. Mai and H. Meng, Integr Biol-Uk, 2013, 5, 19-28. 
2. T. C. Yih and M. Al-Fandi, J Cell Biochem, 2006, 97, 1184-1190. 
3. C. T. Kresge, M. E. Leonowicz, W. J. Roth, J. C. Vartuli and J. S. Beck, Nature, 1992, 359, 
710-712. 
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Chapter 2. Literature Review 
 
This chapter provides an overview on nanomaterials that are currently being designed for 
therapeutic applications, with a special focus on porous silica nanoparticle based 
materials. In section 2.1, a variety of nanomaterial based therapeutics, including 
liposomes, polymeric micelles and nanogels, and inorganic nanoparticles such as gold and 
iron oxide, will be briefly discussed. Section 2.2 focuses on the employment of porous 
silica nanoparticles for therapeutic delivery. The current development on synthetic 
approaches of self-assembled porous silica materials will be overviewed in section 2.3, 
including inorganic porous silica nanoparticles and periodic mesoporous organosilicas. 
Finally, a summary and outlook will be given in section 2.4. 
2.1 Synthesis of porous silica nanoparticles 
2.1.1 Introduction to porous silica nanoparticles 
Porous nanoparticles are solid form of matter containing ordered or disorder pores/voids 
with particle size in nanoscale. Based on the pore size, they can be classified into three 
types: microporous (pore size < 2 nm), mesoporous (pore size = 2-50 nm), and 
macroporous materials (pore size > 50 nm).1 Owing to the high surface area, adjustable 
pore structure and surface chemistry, mesoporous silica nanoparicles (MSNs) are widely 
used in various applications, such as catalysis, separation, adsorption, hard templating, 
therapeutic delivery, since they were firstly discovered in 1990s.2 Biomedical application of 
MSNs have received great progress during the recent decade and a large number of 
MSNs based therapeutic delivery systems have been developed with very promising 
results both in vitro and in vivo.3 Nowadays, researchers are struggling in synthesizing 
novel structured MSNs to achieve better performance. It is believed that the particle size, 
pore size, uniformity and dispersity of MSNs is of great importance to their biomedical 
performance.4 Therefore, good control of particle synthesis is fairly important. 
2.1.2 Formation mechanism of self assembled porous silica 
nanoparticles 
To understand the formation mechanism of self assembled porous silica nanoparticles, 
different characterization techniques have been utilized, including Nuclear Magnetic 
Resonance (NMR), electron paramagnetic resonance (EPR), in situ X-ray diffraction, 
Transmission electron microscopy, Fourier transform infrared spectroscopy (FTIR), N2 
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Sorption, et al. Based on those techniques, researchers have proposed several formation 
mechanisms of self assembled porous silica nanoparticles. 
 
Mobile scientist firstly proposed liquid crystal templating (LCT) mechanism (Fig. 1).1, 2  
They compared the TEM and XRD results of MCM-41 with liquid crystal structure formed 
by surfactant. Due to the similarity of these two structures, they believed that the surfactant 
served as a template during the synthesis process and proposed two possible 
mechanisms: 1) surfactants form spherical micelles first in aqueous solution, followed by 
rod like micelles, which in turn self assemble to form a liquid crystal with hexagonal 
structure. Silica precursors hydrolyse and condense on these liquid crystals to form a 
silica-surfactant composite with hexagonal structure. The porosity was generated after 
removing the surfactants. 2) Surfactants interact with inorganic silica precursors and form 
surfactant-silica composites, which further form a rod like micelle structure. This rod like 
micelle structure will self assemble to a hexagonal meso-structure in aqueous solution. 
The LCT mechanism offered a preliminary understanding on the formation of meso-
structured organic-inorganic composite. In addition, it can be used to explain some 
experimental observations, such as the influence of surfactant concentration and reaction 
temperature on the final product.5-7 
Figure 1 Schematic demonstration of LCT mechanism. (1) Surfactant micelles self 
assemble to hexagonal structure. (2) Surfactant-silica composite micelles self assemble to 
hexagonal structure.1 
 
Nevertheless, as synthesis of porous material has undergone a rapid development, many 
observations cannot be explained by using LCT mechanism. For instance, LCT 
mechanism cannot explain the formation of MCM-41 at a surfactant concentration lower 
than its critical micelle concentration (CMC), wherein no liquid crystal can be formed. 
Moreover, MCM-41type materials can be obtained by using surfactants with short carbon 
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chain, which are unable to self assemble to micelles.8 This observation is in conflict with 
LCT mechanism as well. Hence, LCT mechanism was denied shortly.  
 
Stucky and co-workers proposed a cooperative formation mechanism (CFM) (Fig. 2).9 This 
mechanism demonstrates that the meso-structure was formed as a consequence of 
cooperative assembly between organic surfactants and inorganic silica oligomers. During the 
formation process, silica oligomers interact with cation surfactants through electrostatic 
interaction. Silica oligomers polymerization at the interface results in the change of charge 
density, leading to the approaching of hydrophobic carbon chain. The arrangement of 
surfactants is dependent on the charge matching. The charge density of inorganic phase will 
be altered during the reaction process, which will further influence the structure of the 
inorganic-organic composite. The final structure is determined by the polymerization degree of 
silica oligomers and charge matching and self assembly of surfactants. CFM can explain many 
experimental observations, in particular some mesostructure that not exist in phase diagram of 
surfactants. In addition, CFM can also explain the different type of structural evolution based 
on one surfactant, such as hexagonal and cubic. The CFM are widely accepted as a theoretic 
guidance for synthesis of porous materials. 
  
Figure 2 Cooperative formation 
mechanism. 
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2.1.3 Law of synthesis 
Critical micelle concentration (CMC) 
Generally, surfactants with lower CMC are more favoured to obtain ordered structure.10 If 
the CMC of surfactants is between 0 – 20mg/L, ordered structure can be obtained. Using 
the surfactants with CMC between 20 – 300 mg/L, ordered structure can be obtained by 
decreasing their CMC, such as adding salts. However, it is very difficult to obtain ordered 
structure when CMC higher than 300 mg/L.10 
 
Packing parameter 
The packing parameter (g) have been widely used to predict or explain the structure of 
product.11 g = V/(aol), V is total volume of the whole surfactant molecule, ao is effective 
area of hydrophilic head and l is the length of the hydrophobic tail. This equation has been 
regarded as a good guidance to control the synthesis conditions to obtain a specific 
structure.  When g < 1/3, particles tend to form Pm3n cubic structure and mixed 3-D 
hexagonal structure and cubic structure; when 1/3 < g <1/2, particles tend to form p6mm 
hexagonal structure; when 1/2 < 2/3, particle tend to form Ia3d cubic structure; when g~1, 
lamellar structures are favoured.  
Figure 3 Pore models of mesostructures with symmetries(A) p6mm, (B) Ia-3d, (C) Pm-3n, 
(D) Im-3m, (E) Fd-3m, and (F) Fm-3m12 
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Hydrolysis and condensation 
Hydrolysis:  OH- + Si(OR)4 → Si(OR)3OH + RO- (1) 
 
Condensation:  SiO- + Si(OH)4 → Si–O–Si + OH- (2) 
 
The hydrolysis (1) and condensation (2) play a very important role in silica synthesis and 
are highly related to the pH condition. Hydrolysis of the Si–OR bond in silanes could occur 
both in acid or base. Its rate is lowest near pH neutral conditions and accelerated as the 
pH increase or decrease. For condensation, its rate reach the lowest at the isoelectric 
point (pH = 2) of silanol groups. Below the isoelectric point, the silica species are positively 
charged and the surface charge increases as the pH decreases. When the pH is above 
the isoelectric point, the silica species tend to be negatively charged, and the charge 
density increases along with the pH. These negatively charged silica species tend to 
interact with positively charged surfactants via electrostatic and hydrogen-bonding. As the 
rates of both hydrolysis and condensation are influenced by changing pH levels, the 
optimum pH for hydrolysis is not optimum for condensation. Finding the best balance 
between hydrolysis and condensation is one of the keys to prepared silica nanoparticles 
with uniform morphology, good dispersity and specific structure. 
2.1.4 Hollow silica nanoparticles (HSNs) 
In order to improve the loading capacity of nanoparticles, efforts have been made to 
prepare silica nanoparticles with a hollow cavity that serves as a container to encapsulate 
cargos for various biomedical applications. To date, many synthetic approaches of HSNs 
have been developed. Generally they can be classified into hard templating and soft 
templating. 
 
Hard templating 
Hard templating is the most widely used approach to prepared uniform and 
monodispersed HSNs, which is critical for biomedical applications. The fundamental 
principle of this strategy is to coat silica on a pre-formed solid core followed by core 
removal. Surfactants or any other chemicals capable of co-condense with silica precursors 
can be added to generate a porous silica shell.  
 
Zhao et al.13 reported preparation of uniform hollow mesoporous silica spheres by using 
hematite as a hard template and coated with silica by co-condensation of tetraethoxysilane 
(TEOS) and n-octadecyltrimethoxysilane (C18TMS). After calcinations and HCl etching to 
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remove the core, hollow silica spheres with mesoporous shell was obtained. The particle 
size can be tuned in sub-micrometric range (typically around 100–200nm) and the shell 
thickness can be tuned independently at around 10nm. These HSNs show high drug 
storage capacity (726 mg ibuprofen per gram), owing to their hollow structure.  
 
Following the same concept, Chen et al.14 reported a synthesis of well dispersed HSNs by 
using solid silica nanoparticle as the core. In this system, pore sizes in the shell of hollow 
silica nanocapsules are well-tuned from 3.2 nm to larger than 10 nm. Moreover, the pores 
can be fully filled through the regrowth of the dissoluted silicates by bonding to silanols 
(Si–OH) on the wall surface to generate the nonporous hollow silica nanocapsules. The 
large-sized pore hollow silica nanocapsules exhibit excellent siRNA-loading capabilities 
and intracellular transfection efficiencies in vitro. 
 
Xia and co-workers15 reported the preparation of uniform hollow magnetic mesoporous 
silica spheres with Fe3O4 nanoparticles embedded in the mesoporous shell using 
carboxylic polystyrene latex and Fe3O4 heteroaggregates as the hard template together 
with a coating of TEOS and C18TMS mixture. The particle size of the HSNs is about 370 
nm, and magnetic property is tuneable by adjusting the weight ratios of PS/Fe3O4. In 
addition, the HMMS demonstrates high drug storage capacity and sustained release 
properties. 
 
A big issue of hard templating method is that the removal of the template requires hash 
conditions, such as highly acidic or basic, which limits its application in scaling up 
synthesis. Another problem is particles sizes of HSNs obtained from hard templating are 
relatively large (>200 nm), since decreased particle size may cause severe particle 
aggregation/fusion during the coating process. Since it is generally accepted that ~50nm is 
the optimal particle size for biomedical applications, more efforts are still needed to 
develop uniform and well dispersed HSNs in such size range. 
 
Soft templating 
Soft templating, including micelle templating16 and vesicular templating,17 offers an 
alternative facile and environmental friendly approach for HSNs preparation. Since variety 
of aggregates of amphiphilic surfactants have been extensively studied, they can be 
explored for making hollow silica structures. Soft templating is based on the self assembly 
of surfactants to for a lamellar (e.g vesicular templating) or spherical hollow structure (e.g 
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micelle templating), which serve as a template for silica precursors deposition and form 
HSNs. 
 
Zhu et al.18 reported the block-copolymer micelles templating synthesis of ultrasmall and 
well-dispersed hollow siliceous spheres with uniform particle size of 24.7 nm, a cavity 
diameter of 11.7 nm, and a wall thickness of 6.5nm. The ultrasmall hollow spheres are 
able to load functional components and possess superior endocytosis properties for HeLa 
cells compared to those of conventional mesoporous silica nanoparticles. Another study 
conducted by Ma and co-workers19 demonstrated the one-pot synthesis of PEGylated 
mesoporous silica nanoparticles with tunable sizes around 9 nm based on CTAB micelle 
templating method. Such particles show excellent performance for bio-imaging 
applications. Depite the uniformity and good dispersity of micelle templated HSNs, the very 
small entrance size (< 3nm) on the silica shell is big issue, which significantly limited the 
accessibility of the hollow cavity to load relatively large therapeutic agents.  
 
 
Figure 4 Schematic illustration of formation of vesicles from lamellar structure.20 
Vesicular templating method offers a facile way to prepare HSNs with large entrance size 
since it is firstly reported by Hubert in 200121. As discussed in section 2.1.3, the packing 
parameter (g) offers an important guidance in prediciton of desired morphology and 
structure. The formation of unilamellar composite vesicles is proposed to follow a 
cooperative vesicle templating process between macromolecules and siliceous species,22 
which is base on the closure a lamellar structure with the g is approximately 1. The closure 
is driven by the high surface tension at edge area of the lamellar structure due to the 
existence of hydrophobic tails (Fig 4). Hence, closure from lamellar structure to spherical 
structure can effectively lower the total surface free energy. 
 
Our group previously23 reported a synthesis of siliceous unilamellar vesicles by using 
triblock copolymer P123 as the structural directing agent at a certain ionic strength, pH and 
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temperature conditions. The obtained HSNs show high BSA loading capacity, owing to 
their large entrance size (>10 nm) and high pore volume. Yu et al.24 reported a successful 
preparation of siliceous vesicles with controllable sizes, wall thickness, and shapes by 
adjusting the hydrophilic/hydrophobic ratios of mixed block copolymer templates. By finely 
tune the synthesis conditions, it is also possible to obtain a vesicle and micelle mixed 
structure, which is so called raspberry-like hollow silica nanoparticles.25 Nevertheless, 
severe aggregation of HSNs obtained from vesicular templating is a critical issue, which 
limits their application in therapeutic delivery. A possible solution to this issue will be 
discussed in Chapter 3. 
2.1.5 Rod like SBA-15 silica nanoparticles  
Since SBA-15 type MSNs were firstly discovered in 1998,5 they have drawn much 
attention and have been widely used in various applications including catalysis, adsorption 
and separation. The ordered hexagonal structure and large pore sizes (5-30 nm) are 
considerably beneficial for mass transfer and accommodating large molecules, such as 
therapeutic proteins. The formation mechanism of SBA-15 has been extensively studied. 
The process briefly includes the following three stages. The first stage is the cooperative 
self-assembly of surfactant and silica precursor to form composite aggregates. The model 
of (S0H+)(X+I-)6 pathway has been widely accepted to explain the formation of the nonionic 
surfactant–silica composites at this stage. The transformation from spherical micelles to 
cylindrical micelles occurs due to the increased packing parameter caused by the 
continuous silica condensation. The second stage is colloid–like interaction of these 
surfactant-silica aggregates composites. Further condensation of silica species results in 
interaction of composite aggregates to form a new liquid crystal phase, which grows 
denser with time and finally separated from the water phase.26 The third stage is the 
continuous growth and self assembly of the separated liquid crystal phase into final solid 
mesostructure.26 
 
As an effective therapeutic nanocarrier, it is crucial to decrease the particle size for two 
reasons: (1) The decreased channel length will lead to shortened diffusion paths of cargos, 
resulting in lowered possibility of pore blockage; (2) Smaller particle size favours more 
efficient cellular uptake. Hence, much effort has been made to prepared small SBA-15 
particles while maintain ordered hexagonal structure and large pore size.  
Homogeneously sized SBA-15 with 10 porous channels in width and ranging from 300 to 
600 nm in length is reported by Nazar et al. by using a low concentration of P123 
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(EO20PO70EO20) and tetraethyl orthosilicate (TEOS).27 Lu et al. have introduced an elegant 
synthesis of mondispersed rodlike SBA-15 with different length (0.3~4μm) by tuning the 
concentration of hydrochloride acid (HCl) in the presence of glycerol.28 Moreover, the 
particles they have prepared with short length exhibited rapid lysozyme immobilization and 
high adsorption capacity. A very rapid synthesis of SBA-15 rods variable particle length 
(400~600nm) and width (100~400nm) has been achieved by varying the HCL 
concentration in the presence of heptanes and NH4F.29 The reaction time can be decrease 
to 1 h simultaneously retain the pore size and morphology perfectly.  Recently, Yin et al. 
reported a convenient route to prepare rodlike SBA-15 with varying lengths (0.6~3.0μm) 
and widths (0.26~0.4μm).30 Their findings are consistent with previous reports that the 
SBA-15 rods with shortened length exhibit very rapid enzyme adsorption and high 
adsorption capacity.  
 
However, current achievement on synthesis of SBA-15 rods is still larger than the 
satisfactory requirement of sufficiently small particle size (< 200 nm) for efficient cellular 
uptake. In addition, SBA-15 silica particles with large particle sizes have limitation in large 
molecular diffusion and adsorption capacity. Hence, the development of small sized SBA-
15 is in great demand. This part will be demonstrated in Chapter 4. 
2.1.6 Periodic mesoporous organosilicas  
To enhance the functionality of porous silica materials, considerable efforts have been 
made to expand the framework compositions. The hybridization of inorganic and organic 
species on molecular level offers good opportunities for developing functional materials 
because their cooperative and synergetic effects, as well as the compatibility of different 
functionalities.31 In this context, three groups independently reported a new class of 
inorganic and organic hybrid mesoporous materials known as periodic mesoporous 
organosilicas (PMOs) in 1999.32-34 In PMOs, the organic groups are incorporated within 
the framework as bridges between the Si atoms. PMOs can be synthesized by hydrolysis 
and condensation reactions of bridged organosilica precursors via the cooperative self-
assembly process, which is similar to the preparation of MSNs. Thousands of papers have 
been published since the first discovery of PMOs and most of them focus on the 
applications including catalysis, adsorbents, separation and low-k films. Only very limited 
papers have reported the potential application of PMOs for therapeutic delivery, probably 
due to the difficulty in synthesis of small sized (< 500 nm) and well dispersed PMOs.  
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Lu and co-workers35 reported the synthesis of PMO hollow spheres with highly ordered 
mesoporous wall structure, tunable particle size, and wall thickness by using CTAB/FC-4 
dual templating approach. Their following work further demonstrated that PMO hollow 
spheres have higher drug loading capacity and more sustained drug release behaviour 
compared to inorganic MSNs and organic mesoporous silica nanoparticles.36 
 
Urata et al.37 reported well dispersed colloidal mesoporous nanoparticles with ethenylene-
bridged silsesquioxane frameworks with a uniform diameter of ∼20 nm. The nanoparticles 
had higher hydrolysis resistance under aqueous conditions and lower hemolytic activity 
toward bovine red blood cells than colloidal mesoporous silica nanoparticles, presumably 
due to the decreased density of silanol groups. This enhanced stability towards aqueous 
solution and hemo-compatibility confirms the PMOs as promising nanocarriers for 
therapeutic delivery.  
 
A general synthetic procedure for highly ordered and well-dispersed PMOs was reported 
by Guan and co-worker.38 By changing the bridging group in the silica precursors, the pore 
structures of the as-made particles can be tuned to three-dimensional hexagonal 
(P63/mmc), cubic (Pm3n), two-dimensional hexagonal (P6mm), and wormlike structure. 
The size range of the nanoparticles can also be adjusted from 30 nm to 500 nm. The 
PMOs nanoparticles obtained in this study show good thermal stability, good dispersion in 
low polarity solvent, high adsorption of small hydrophobic molecules, low cytotoxicity and 
excellent cell permeability, which offers great potential for biomedical applications. 
 
Very recently, Chen and co-workers39 synthesized monodispersed phenylene-bridged 
hollow PMOs with particle size of ~450 nm via silica-etching strategy. The 
histocompatibility of hollow PMOs was also demonstrated for up to two months. 
Furthermore, for the first time, they introduced PMOs into nano-biomedicine for efficient 
intracellular delivery of hydrophobic silibinin for anti-metastasis of cancer cells. 
 
Despite that several literatures have demonstrated the great potential of PMOs for 
therapeutic delivery, current achievement on synthesis of small sized PMOs is still limited 
to small pores (< 5nm), which is very difficult to encapsulate large bio-molecules, such as 
proteins, not to mention delivery of such therapeutic agents. In this context, we utilized a 
biphase synthesis system to prepared uniform well dispersed PMOs with large pore sizes, 
which will be discussed in chapter 5. 
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2.2 Silica based nanocarriers for therapeutic delivery 
As one of the most attractive and promising inorganic system, porous silica nanoparticles 
has been extensively studies in recent decades and abundant positive results have prove 
their potential application for drug-delivery systems (DDSs). The utilization of MCM-41 for 
DDSs was firstly reported in 2001.40 Porous silica nanoparticles have been regarded as 
potential therapeutic carriers due to the following features3 :  
(1) A high pore volume to accommodate sufficient amount of therapeutic agents 
(2) A high surface area, which allows high possibility of interaction between silica 
nanoparticle and therapeutic agents; 
(3) A surface with silanol groups that can be functionalized for multiple purpose, such 
controlled release, enhanced bioavailability, tumour targeting, et al. 
(4) A certain degree of Si-O-Si cross-linking matrix that possess biodegradability.   
2.2.1 The influence of texture properties on performance 
2.2.1.1 Particle size and Morphology (Aspect ratio) 
Particle size is an important parameter in designing advanced therapeutic delivery 
systems, because it is highly related to the mechanism and rate of cell uptake of a 
nanoparticle and its ability to permeate through tissue. For silica nanoparticles, the size 
effects on cellular uptake have been firstly investigated by Jin et al.41 They prepared silica 
nanoparticles with continuously tuneable particle size in the range of 20-100 nm for 
evaluation of bio-imaging applications. Their results clearly demonstrated that the small 
particles (23±3 nm) penetrate the cells faster than large particles (85±5 nm) after 
incubation for 40 min. The large silica nanoparticles tend to be physically adsorbed on the 
outer cell surface while small NPs penetrated the cell membrane and accumulated evenly 
throughout the cytosol.  
 
Later, Mou group42 synthesized monodispersed MSNs with various uniform sizes ranging 
from 30 to 280 nm. Cellular uptake of MSNs of various sizes was investigated by confocal 
laser scanning microscopy (CLSM) and inductively coupled plasma mass spectrometry 
(ICP-MS) analysis, which revealed that uptake is particle-size-dependent and the 
maximum uptake by cells occurs at a nanoparticle size of 50 nm. These findings 
suggested that MSNs 50nm in diameter may be the most suitable candidate to serve as a 
carrier for further studies in biological applications. 
 
In addition to the particle size, the particle morphology, or aspect ratio, also play an 
important role in biomedical applications. Huang et al.43 prepared three different shaped 
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monodispersed MSNs with different aspect ratios (1, 2, and 4). They found that particles 
with larger aspect ratios were taken up in larger amounts and had faster internalization 
rates. Also, particles with larger ARs had a greater impact on different aspects of cellular 
function including cell proliferation, apoptosis, cytoskeleton formation, adhesion and 
migration. Meng and co-workers44 provided a systematic study on the effect of aspect ratio 
on the therapeutic delivery efficiency. They demonstrated the aspect ratio of rod-shaped 
particles determines the rate and abundance of MSNP uptake by a macropinocytosis 
process. Furthermore, MSNs with aspect ratio 2.1-2.5 were clearly more efficient for 
paclitaxel or camptothecin delivery and generation of cytotoxic killing in HeLa cells. 
Another report from Li group45 demonstrated that the cell uptake pathway is highly related 
to the particle shape. Spherical particles preferred to be internalized via the clathrin-
mediated pathway, whereas MSN with larger aspect ratios (ARs) favored to be internalized 
via caveolae-mediated pathway, which could explain their different uptake kinetics. 
  
2.2.1.2 Pore size 
As nanocarriers for therapeutic delivery, it has been well documented the pore size of 
porous silica nanoparticles significantly influence the cargo loading and release. When 
MCM-41 was first used for drug delivery,40 C12TAB and C16TAB as structure directing 
agents for synthesis of different pore sized MCM-41. The MCM-41 with larger pore size, 
obtained using C16TAB, released 68% of the loaded ibuprofen after 24 h in simulated body 
fluid (SBF), while MCM-41 obtained with C12TAB released only 55% of the drug after the 
same period of time. A further study conducted by the same group shown that the 
influence of pore size for drug release is not only applicable in 2D hexagonal structures, 
but also to 3D cubic symmetry.46 Andersson et al.47 reported the influence of the pore 
connectivity and pore geometry of the materials, and the aqueous stability of the matrix on 
the release process. They concluded that structures containing cage-like pores are the 
most promising nanocarriers for long-term drug delivery.  
 
For encapsulation of large bio-molecules, such as proteins, the role of pore size for cargos 
loading and release become even more significant. If the cargo is smaller than the pore 
size, it will enter the pores and the internal surface area and pore volume can be utilized, 
thereby higher loading amount can be obtained. If not, it will adsorb only on the outer 
surface, thus loading capacity will be dramatically decreased. Hodnett et al. reported that 
when the pore size of MCM-41 was 4.5 nm, the loading capacity towards cytochrome c is 
8 mmol/g, while the loading capacity was less than 1 mmol/g under the same conditions 
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when the pore size was reduced to 2.8 nm.48 Recently, Na and co-workers49 reported an 
efficient si-RNA delivery system using MSNs with average pore size of 23 nm, which 
possess loading capacity two times higher than MSNs with pore size of 2 nm. In addition 
to the high loading capacity, the encapsulation of si-RNA can effectively enhance its 
stability and maintain its activity in vitro. However, particles with pore size significantly 
larger than the cargo will not benefit for the performance. Mou group50 reported that MSNs 
with pore size of ~2.5 nm, which is very close to cytochrome c size, possess better 
capability of improving the protein  hydrothermal stability and catalytic activities than 
porous supports with small pores (0.7 nm) or very large pores (9 nm).  Recently our 
group51 reported RNase A delivery using silica vesicles with different entrance size. The 
results show that silica vesicles with an intermediary entrance size of 6.2 nm showed 
higher load capacity and sustained release profile compared to silica vesicles with 
entrance size of <3.9 nm and 14.2 nm. Therefore, carefully control on the pore size and a 
snug fit of cargos inside the pores are important to achieve improved performance.  
 
2.2.1.3 Composition and surface functionlization 
The keystone in the development of silica porous materials as therapeutic nanocarrier is 
the functionalization of the surface or incorporation of the matrix with organic groups, 
which provides numerous possibilities to control therapeutic agents adsorption and 
release. Porous silica nanoparticles can be grafted by various organic silanes through the 
surface silanol groups, or directly embedded by using bridged silanes.   
 
Surface functionalization is the most developed method to control release via increasing 
the interaction between therapeutic agents and the surface. Several research groups52, 53 
reported the functionalization of MCM-41 and SBA- 15 with amino groups as an effective 
method to control IBU release. The electrostatic interaction between the negatively 
charged carboxy groups in IBU and the positively charged amino groups on the silica 
surface offers effective control on the release rate of IBU from porous nanoparticles. The 
same mechanism is also applicable on carboxylic acid functionalized porous silica 
nanoparticles to adsorb drug that contains amino group, such as famotidine, showing an 
adsorption capacity dependent on the degree of functionalization.54 This electrostatic 
based strategy is also widely in gene delivery, since si-RNA molecules are highly 
negatively charged. Cationic functional groups, such as Poly-L-lysine,55 polyethylenimine 
(PEI),56 and amino49 are covalently or physically graft on silica surface to improve loading 
capacity, as well as to facilitate endosome escape. Manhony et al.57 highlighted the 
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importance of amino functionalization on MCM-41 nanoparticles for enhanced ovalbumin 
binding, thus sufficient immune response can be achieved.    
 
In addition to the electrostatic based surface modification, hydrophobic funtionalization 
offers another effective strategy for therapeutic agents loading and controlled release. 
Doadrio et al.58 reported the controlled release of erythromycin from octyl and octadecyl 
functionalized SBA-15. Such a hydrophobic functionalization resulted in a decreased pore 
size and wettability, which allowed an effective control on the release rate of erythromycin. 
They found the release rate was one order of magnitude lower than that of 
nonfunctionalized SBA-15. Bale and co-workers reported the octadecyl funtionalized 
stober spheres for efficient intracellular delivery of a hydrophobic cytotoxic protein – 
RNase A.59 Very recently, our group also reported the octadecyl funtionalized silica hollow 
spheres allowed very high RNase A loading amount (~850 mg/g) and sustained release 
for more than 3 days.51 Such a nanoparticle-protein composite induced significantly 
enhanced cell inhibition compare to bare protein due to its cell membrane 
impermeability.51   
 
Incorporation of organic groups in silica frameworks, known as periodic organosilicas 
(PMO), offers another strategy for efficient cargo loading and controllable release. Lu and 
co-workers36 reported that ethane-bridged hollow PMO spheres exhibit higher loading 
capacity and a slower release rate of cisplatin compared with conventional MSNs and solid 
spheres owing to their empty cores and hydrophobic interaction between drug and organic 
groups. Asefa and co-workers60 reported that ethane bridged PMO possess significantly 
higher loading capacity for both rhodamine6G and cisplatin than MCM-41 or SBA-15 and 
sustainied drug release profile.  Recently, Wu and co-workers61 prepared benzene-bridged 
PMO nanoparticles with abundant carboxylic groups (~ 80%) in the matrix. Such materials 
showed excellent loading capacity and very slow release of doxorubicin owing to the 
combination effect of π-π interaction and electrostatic interaction, suggesting the potential 
of PMOs for cancer therapy. 
2.2.2 Stimuli responsive therapeutic delivery systems 
Owing to the interesting features mentioned above, porous silica nanoparticles are 
regarded as excellent candidates for therapeutic delivery systems, and much effort has 
been carried out on this topic during recent years. One of the main problems of silica 
based therapeutic delivery system at present is the burst/premature release of therapeutic 
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agents before reaching the targeted tumour site, which significantly limit the therapeutic 
efficacy.62, 63 In this context, stimuli-responsive systems that exhibit very low premature 
release have been developed to address this issue. The general strategy used in these 
systems is to cap the pores that loaded drugs with “gatekeepers”, resulting in drug 
molecules unable to be leach out due to the pore blockage.  The gatekeepers are 
removable under exposure to stimuli, triggering the release of loaded therapeutic 
molecules. To date, several types of stimuli responsive therapeutic delivery systems has 
been developed, such as pH responsive, redox responsive, and thermo-responsive 
system. 
 
Among vigorous silica based stimuli-responsive systems, pH responsive systems received 
the most investigation since it was firstly reported in 2005.64 It is well known that the 
cancer tissues have more acidic condition (pH 6.5-7.2) compared to normal tissues (pH 
~7.4), and more acidic in endosomes (pH 5-6) and lysosome (pH 4-5).65 Taking the 
advantage of the subtle difference between normal tissues and cancer tissues, a pH 
sensitive system offers an effective way to control the drug release behaviour. Differencet 
capping agents such as CdS,66 ZnO67 and molecular machines,68 69, 70 have been used to  
establish a pH responsive drug delivery system. Zink and co-workers71 demonstrated a pH 
responsive system based on nanovalve capped mesoporous silica nanoparticle. N-
methylbenzimidazole stalks binded with β-CD serve as a cap on the pores to prevent the 
drug leaching. The deprotonation occurred at acidic condition (pH<6) caused the 
dissociation of β-CD caps and release of drug. The Doxorubicin loaded nanoparticles 
showerd effective cell inhibition, which was attributed to the significant cargo released 
caused by lysosomal acidification. Very recently, Qu et al.72 developed a Luminescent 
cabon dots gated MSNs through electrostatic interaction. The dissociation of the C-
Dots@MSPs complex and release of a large number of DOX from the nanospheres can 
be triggered by at mildly acidic condition due to the protonation of carboxylic acid species. 
In this system, the cabon dots not only serve as a capping agent to prevent premature rug 
release, but also exhibit strong luminescence for bio-imaging. 
 
Redox responsive systems are another well studied candidates for controllable therapeutic 
delivery owing to the huge difference of concentrations of glutathione in extracellular 
compartments (~2-10 μM)65 and intracellular compartments (~2-10 mM)65, and in tumor 
tissues compared with normal ones. Redox responsive systems are mostly based on the 
utilization of disulphide bond, which prone to rapid cleavage by glutathione, thus redox 
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sensitivity can be achieved. Kim et al.73 developed redox-responsive MSNs with 
cyclodextrins gatekeepers covalently connected onto the particle surface via disulfide 
bond. Their results show that the glutathione-induced controlled release of DOX from the 
pore can significantly enhance the cytotoxicity of this anti-cancer drug. Quignard and co-
workers74 have introduced the disulphide bond into the silica framework and achieve a 
intra-cellular degradable property, which is responsive to dithiothreitol. In addition to 
disulphide bond, some other redox responsive systems are also developed. Very recently, 
Wang et al.75 discovered that Mn3O4 nanoparticles are redox responsive and can be 
reduced to Mn2+. They utilized Mn3O4 nanoparticles as a capping agent on the surface of 
MSNs. These Mn3O4 nanoparticles can not only induced redox triggered drug release, but 
also allow both in vitro and in vivo magnetic resonance imaging owing to their magnetic 
properties.  
 
Thermoresponsive porous silica based systems have been developed by coating thermally 
active polymers, such as poly(Nisopropylacrylamide) (PNIPAm), which is mostly used in 
thermoresponsive systems.76, 77 The resulting nanoparticle-polymer composites show 
temperature dependent release of cargos because PNIPAm can undergo a phase 
transition from a hydrophilic, water-swollen state to a hydrophobic, globular state when 
heated above its lower critical solution temperature (LCST), 32–33 °C in water. 
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2.3 Other nanocarriers for therapeutic delivery 
2.3.1 Liposomes  
 
Figure 5Types of nanocarriers for drug delivery A, polymeric nanoparticles: polymeric 
nanoparticles is able to conjugate or encapsulated therapeutic agents. B, polymeric 
micelles: amphiphilic block copolymers self assemble into micelle structure with an inner 
hydrophobic core, serving as a therapeutic agents container, and an outer hydrophilic shell 
enhance dispersity in aqueous phase.  C, dendrimers: synthetic nanosized polymers with 
multiple branched monomers that arranged in a radial manner. D, liposomes: self-
assembled lipid bilayers into closed spherical structure, in which the lipid surface and/or 
the inner cavity can be used to conjugate/encapsulate therapeutic agents. E, viral-based 
nanoparticles. F, carbon nanotubes.78 
 
Liposomes, firstly discovered approximately 40 years ago by Bangham79, are comprised of 
lipid bilayers which self-assembled into closed colloidal structures with spherical 
morphology wherein the hydrophilic region of the amphiphilic building blocks face the 
interior and exterior of this colloidal structures , while the hydrophobic region occupies the 
inner area in a parallel manner (Fig.5 D).  Owing to the amphiphilic nature, liposomes are 
encapsulated both hydrophilic drugs and hydrophobic drugs in its cavity and membrane, 
repectively. To date, a number of liposome-based systems have been extensively 
developed. Typical examples are the anthracyclines doxorubicin (Doxil, Myocet) and 
daunorubicin (DaunoXome), which have been approved for the treatment of metastatic 
breast cancer and AIDS-related Kaposi’s sarcoma.80-82 A drawback of liposomes for 
clinical applications is that those nanoparticles with particle size of approximately 100–200 
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nm will be rapidly eliminated by the mononuclear phagocyte system in blood stream 
without proper protection.79 As a result, liposome based systems generally need the 
surface functionalization of biocompatible polymers, such as polyethylene glycol (PEG), to 
increase the blood circulation duration. For instance, in the case of a commercial product, 
Doxil, the circulation time can be increased from 30 min to 80 h.83 Under the protection of 
polymers, the “marking” of the liposomes with opsonin proteins can be effectively 
prevented, leading to decreased macrophage recognization, which is believed as a critical 
step in clearance of foreign guests.83 As a result, the circulation time can be prolonged, 
which is beneficial to the passive or active accumulation into tumour cells.   
 
Taking advantage of interesting properties of liposomes, many advances have been made 
in the development of liposome systems for therapeutic delivery. Recently, Lombardi et 
al.84 have reported a doxorubicin and gemcitabine dual-loaded PEGylated-liposomes 
system in patients with advanced hepatocellular carcinoma in phase II clinical trials, 
wherein 7% patients had a complete response, while 17% patients had a partial response.  
 
Kono and coworkers85 synthesized thermoresponsive multifunctional PEGylated-
liposomes using thermosensitive polyether chains, capable of releasing doxorubicin at 
temperatures above 40 °C in tumor-bearing mice. A gadolinium-chelating dendrimer was 
installed on the surface of the liposome to monitor the tumour accumulation and the T1-
weighted Magnetic Resonance Imaging (MRI) signal intensity. Based on this approach, the 
tumour growth was significantly suppressed, where the tumour volume measured after 8 
days was less than one-fourth of that in the control group, where liposome was absent and 
mild heat was employed. 
 
Ahmady and co-workers86 reported leucine zipper peptide-liposome hybrids, which 
combine the advantages of traditional temperature-sensitive liposomes with the 
dissociative, unfolding properties of a temperature-sensitive peptide. The hybrid vesicle 
serum stability was significantly enhanced in vitro and in vivo by anchoring of the 
temperature-sensitive peptides into lipid bilayers without affecting their thermoresponsive 
character. Owing to the improved serum stability, tumor drug accumulation was also 
enhanced in the presence of hyperthermia in tumor-bearing animals. 
 
Also promising are thermoresponsive bubble generating liposome system reported by 
Chen et al..87 The emergence of permeable defects in the liposome bilayer as a result of 
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the generation of carbon dioxide bubbles through decomposition of ammonium 
bicarbonate at ~ 42°C triggers rapid release of drug. Also, the ultrasound imaging of 
tissues was improved due to the hyperechogenic features of carbon dioxide bubbles. 
2.3.2 Polymeric micelles and nanogels 
Polymeric micelles are comprised of amphiphilic polymer building blocks, which self-
assemble to form spherical nanoparticles with hydrophobic core and hydrophilic shell. 
Basically polymeric micelles and liposomes have similar supramolecular structure, while 
polymeric micelles only possess a monolayer and the entire internal region is hydrophobic 
(Fig. 5B).85 Due to this structural difference, polymeric micelles have a smaller particle size 
(10 – 100 nm) than liposomes. Moreover, the inner hydrophobic can only be used to 
encapsulate hydrophobic drug, while hydrophilic drug prefer to stay on the outer 
hydrophilic shell. 83 The small particle size of polymeric micelles is beneficial for a higher 
penetration capability into leaky vasculature of tumours than other larger nanocarriers 
such as liposomes. However, the small particle sizes also cause a relatively low loading 
capacity and burst release, thus low intracellular drug dosage at tumour site. To date, 
much effort has been made for the development of polymeric micelles with enhanced 
tumour site targeting ability and drug loading capacity. A widely used strategy to enhance 
the cancer cell targeting ability is to conjugate targeting ligands on the surface, such as 
PEG-folic acids, peptides, and sugars, due to their specific affinity to overexpress 
corresponding receptors.88  
 
Nishiya and coworkers89 recently conducted a Phase I clinical study using PEGylated 
micelles to show the sustained release rate of cisplatin from polymeric micelles, which in 
turn gives a significantly supressed toxicities compare to free cisplatin administered 
intravenously.  
 
Lavasanifar and Xiong90 reported a PEO-b-polyester-based micellar nanomedicine for 
traceable co-delivery of siRNA and DOX to multidrug resistant cancer cells in mice. This 
multifunctional nanocarrier has virus-like shell for cell specific recognition and efficient 
cellular uptake and incorporated fluorescent probes for in vitro and in vivo tracking. These 
micelles could release intact DOX by a pH-triggered mechanism. With the functionalization 
of RGD/TAT peptide, these micelles demonstrated significant cellular uptake, improved 
intracellular DOX therapeutic efficacy in these DOX-resistant cells. 
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Another type of polymer-based nanoparticle with great progress in recent decades is 
polymeric nanogel. Different from micelles and liposomes, the network of polymeric 
nanogel consist of cross-linked or self-assembled polymers, which have higher loading 
capacities, greater stability, and stimuli responsive release of payload. Due to the diverse 
composition of polymeric nanogels, they provide much more options in properties than 
other nanocarriers, such as polymeric micelles and liposomes, in order to enhance their 
bioavailability, biocompatibility, drug loading capacity, controllable release and active 
tumour site targeting ability. In terms of drug loading, three ways are commonly used: (1) 
physical adsorption based on electrostatic interaction, hydrogen bonding, hydrophobic 
interaction or π-π interaction; (2) covalent bonding to either the inner or outer surface of 
the nanoparticle; (3) controlled self-assembly of drug and polymer compounds. Regarding 
the release of drug, abundant literatures have report the polymeric nanogels based stimuli 
responsive drug delivery systems, such as pH, temperature, redox, light, enzyme, et al.. 
For example, faster release can be initiated in response to (1) changes in pH, which 
changes the hydrophobicity/ hydrophilicity of polymers and results in swelling or chagens 
the surface charge of polymers and lead to decreased interaction with drugs, (2) an 
increase of redox concentration can lead to the breakage of disulphate bond with drugs, 
which is the most extensively studied redox responsive bond, thereby fast release can be 
triggered, or (3) changes in temperature which cause a sharp change in the properties of 
at least one of the composition in the network, which in turn triggers the increased porosity 
and release of the cargo. In order to enhance the drug dosage at tumour site and 
decreased side effects, tumour targeting agents, such as folic acid, can be conjugated to 
the nanoparticles for corresponding overexpressed receptors. 
 
Bronich, Kabanov, and coworkers91 reported synthesis of nanogels by using diblock 
copolymer poly(ethylene oxide)-b-poly(methacrylic acid) (PEO-b-PMA) through polyion 
complexation and cross-linking of doubly hydrophilic block ionomer. Folic acids were 
conjugated to nanogels to enhance the specificity of nanocarrier to targeted cells 
expressing folate receptor. Their results showed the superior anti-tumour efficacy of 
cisplatin-nanogel comsite towards a xenograft tumor with decreased renal toxicity.  
 
Chen et al.92 reported one step synthesis of redox-responsive disulphate cross linked 
PEG-poly(amino acid)s star copolymers. The release of DOX from the nanogels was found 
faster in the presence of higher concentration of glutathione due to the cleavage of 
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disulphate bond. The glutathione triggered intracellular DOX release significantly enhance 
in vitro cell growth inhibition, while bare nanogels showed excellent biocompatibility. 
 
A recent work conducted by Chen group93 showed the preparation of reduction and pH 
responsive disulfide-cross-linked PEG-polypeptide copolymers. The nanogels showed 
very high DOX loading capacity due to electrostatic interaction. The presence of reduction 
agent and low pH condition can effectively trigger the release of DOX from DOX-loaded 
nanogel, thereby higher cellular proliferation inhibition efficacy was achieved toward 
glutathione monoester treated HeLa and HepG2 cells as compared to unpretreated and 
buthionine sulfoximine pretreated cells. Moreover, the system they developed showed 
lower hemolysis activity compare to free DOX, further confirming the suitability for clinical 
chemotherapy. 
2.3.3 Gold nanoparticles 
Gold nanoparticles are widely used for photothermal therapy due to their ability to convert 
light with a certain wavelength to heat, which can effectively kill the cancer cells. By 
changing the particle size or morphology, or employing a silica-gold core-shell structure, 
the absorption wavelength can be shifted to the near infrared (NIR) region with longer 
wavelength (650–900 nm),83 which is advantageous to enhance the phototherapy efficacy, 
in particular for killing deep cancer tissues owing to the stronger tissue penetration ability 
of NIR.  
 
Halas group94 has demonstrate the photothermal therapy towards SK-BR-3 cancer cells by 
using SH-PEG-passivated gold nanoparticles with a core-shell structure possessing a 
maxmum absorbance at 820 nm wavelength. In vivo, in the presence of AuNS and NIR 
irradiation, the temperature could reach 37.4 ± 6.6 °C at a depth of 2.5 mm under 5 min 
exposure. This temperature was able to cause irreversible tissue damage with 10 to times 
less laser dosage used with with Indocyanine green dye. 
 
It is well known that by tuning the shell thickness and core radius, the Au based core shell 
nanoparticles can be designed to scatter/absorb light wavelength in a broad range 
including the NIR, which offers the possibility of nanoparticles with simultaneous diagnostic 
and therapeutic properties. Drezek group95 reported a nanoshell based all-optical system 
for cancer imaging and therapy applications. Immunotargeted nanoshells was designed for 
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both light scattering and adsorption, to simultaneously provide cancer imaging and 
photothermal therapy in breast carcinoma cells that overexpress HER2. 
 
Huang and co-workers96 reported the utilization of gold nanorods as dual imaging and 
therapy agents due to their capability of absorption and scattering of NIR light. The surface 
plasmon resonant absorption spectroscopy and light scattering imaging were used to 
distinguish HSC and HOC malignant from HaCaT non-malignant cells due to the 
overexpressed EGFR on the malignant cell surface. After incubation of cells in the 
presence of NIR at 800 nm and EGFR antibody conjugated Au nanorods, the cell 
distruction due to the photothermal was observed.  The light energy required to cause 
efficient malignant cell destruction was about half of that required to cause death to the 
nonmalignant cells owing to the enhanced cell uptake of Au nanorods. 
  
2.3.4 Iron oxide 
Iron oxide nanoparticles have recently emerged as attractive nanocarrers for cancer 
therapy due to their superparamagnetic property, allowing the therapeutic nanomedicine to 
be tracked using magnetic resonance imaging (MRI) and simultaneously improved tumour 
targeting.  
 
Abdalla et al.97 reported an uPAR-targeted iron oxide nanoparticles system for the efficient 
noscapine delivery into prostate cancer cells. The nanoparticles can selectively bind to 
uPA receptor and uptake by PC-3 cells due to the hightly specific and selective ATF of the 
uPA receptor. The therapeutic efficacy of noscapine loaded in nanoparticles was improved 
6 fold compared to free drug. In addition, these multifunctional iron oxide nanoparticles can 
be tracked by NIR-MRI dual imaging, indicating a promising platform for targeted drug 
delivery. 
 
In order to prolong the circulation time in blood stream, PEG is commonly used for surface 
functionalization of iron nanoparticles with enhance bioavailability.98 Similar to other 
nanocarriers mentioned above, the targeting ligands, such as folic acid, phosphonic acid 
can be conjugate to the surface to improve the cancer cell specific uptake.99 Some studies 
also showed the possibility to use iron oxide nanoparticles as the capping agent on 
mesoporous silica nanoparticles for a stimuli-responsive release system.100 By coating iron 
oxide nanoparticles with thermal sensitive polymers, a thermal responsive polymer metal 
oxide drug delivery system with magnetic guided targeting capability as well as magnetic 
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resonance imaging was successfully developed.101 Sun and co-worker reported a porous 
hollow Fe3O4 nanoparticles based drug delivery system with targeting capability and 
controlled drug release properties due to the magnetic property and low stability in acidic 
condition, respectively.102 
  
2.4 Summary  
Porous silica nanoparticles are regarded as promising nanocarriers for therapeutic delivery 
due to their tuneable pore size, high surface area, large pore volume and ease of surface 
functionalization. The formation of porous silica nanoparticles is generally accepted 
through a cooperative formation mechanism and the final structure can be briefly predicted 
by packing parameter. Synthesis approaches for three types of porous silica 
nanomaterials including hollow silica spheres, SBA-15 nanoparticles and periodic 
mesoporous organosilicas were reviewed, with a particular focus on their biomedical 
applications. The influence of particle size, morphology (aspect ratio), pore size and 
chemical composition/functionalization on nanomaterials biomedical performance, such as 
cell uptake efficiency, loading capacity and release behaviour was discussed, which is 
important to design advanced therapeutic nanocarriers. Afterwards, some typical stimuli-
responsive therapeutic delivery systems are briefly reviewed, including pH sensitive, 
thermo sensitive and redox sensitive systems. Finally, other commonly used nanocarriers  
for therapeutic delivery were listed with a brief introduction.  
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Chapter 3. Synthesis of Silica Vesicles with Small Sizes and 
Reduced Aggregation for Photodynamic Therapy 
 
Introduction 
This chapter reports the facile synthesis of silica vesicles (SVs) of ~30 nm with reduced 
aggregation using binary surfactant P123 and L121 and mixed silica source of TEOS and 
TPOS.  The FTIR results as a function of reaction time evidence that the reduced inter-
32 
 
particle aggregation is attributed to the incompletely hydrolysed TPOS, where the 
presence of propoxy group on the particle surface can effectively prevent their cross-
linking. Furthermore, in order to demonstrate the drug delivery application, SiPC were 
chosen as a model drug and loaded in the SVs.  They shows very high drug loading 
capacity of ~40%, which is attributed to the large pore volume as a result of the hollow 
structure. Cell studies of SiPC loaded SVs shows efficient intracellular delivery of drug as 
directly visualized by confocal images. According to the cytotioxicity assay, the efficient 
cell inhibition in the presence of SiPC loaded SVs further confirms the potential application 
of our materials as effitient drug delivery vehicles. 
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Chapter 4. Synthesis of SBA-15 rods with Small Sizes for 
Enhanced Cellular Uptake 
 
Introduction 
Since the small sized spherical silica nanoparticles is favourable in terms of cell uptake as 
we discussed in previous chapter, in this chapter, we report a facile synthesis of small 
sized SBA-15 nanoparticles with rodlike morphology. By finely tune the synthesis pH in a 
narrow range from 3.40-3.88, SBA-15 rods of 80-200 nm in length, ∼ 30 nm in width and 
pore size of 8.3 nm are obtained.  We propose that the formation the small sized rods is 
associated to the structural evolution from rodlike to vesicular structure, which can be 
obtained by a small increase of pH to 3.98. Furthermore, SBA-15 rods prepared in this 
study demonstrate higher adsorption capacity towards large protein molecules such as 
bovine serum albumin and lysozyme, and enhanced cellular uptake efficiency in human 
osteosarcoma cancer cells compared to traditional SBA-15 with relatively larger particle 
sizes and MCM-41 with smaller pore sizes. 
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Chapter 5. Biphasic Synthesis of Large-pore and Well-
dispersed Benzene Bridged Mesoporous Organosilica 
Nanoparticles for Intracellular Protein Delivery 
 
Introduction 
Based on our previous results, sufficiently large pore size, small particles size and high 
dispersity are crucial factors for high performance of nanocarriers for intracellular 
therapeutics delivery. In order to further enhance the cargo loading capacity and release 
profile, we designed mesoproous organosilica nanoparticles (MOSNs) by incorporating 
organic functional groups, which possess higher affinity towards hydrophobic therapeutics 
though hydrophobic interaction and/or π-π stacking. In this chapter, a facile biphase 
synthesis approach has been developed to prepare large pore (4.6-7.6 nm) well dispersed 
MOSNs with uniform particle size of ~50 nm. The dual roles of the upper oil phase, 
including swelling mesopores and facilitating surfactant/organosilica assembly, are 
proposed.  With respect to biomedical application, MOSNs-7.6 show improved adsorption 
capacity and more sustained release profile of RNase A than that of MOSNs-4.6.  The 
efficient cell uptake performance of MOSNs-7.6 is evidenced by CLSM image. RNase A 
loaded MOSNs-7.6 exhibits significantly enhanced cell inhibition compared to pure RNase 
A at a very low effective dosage of 4 μg ml-1, Thus, the large pore MOSNs based protein 
delivery system is expected as promising platform for cellular delivery of various large 
biomacromolecules. 
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Mesoporous organosilicas are a new class of mesoporous materials with the organic/inorganic 
components homogeneously distributed in the framework at the molecular level,[1] which have 
applications in various fields such as adsorption,[2-4] catalysis,[5-7] controlled drug release,[8, 9] 
sepeartion,[10] and enzyme immobilization.[11] Recently, the study of mesoporous organosilicas 
based materials as efficient therapeutic delivery nanocarriers has been a hot topic, because the 
presence of homogeneously incorporated organic groups offers unusual properties when compared 
to mesoporous silica.[1] Mesoporous organosilica nanoparticles (MOSNs) are particularly 
interesting, especially with small sizes around 50 nm, which was reported as the optimal particle 
size for efficient cellular uptake.[12] However, compared to rapid progresses in mesoporous silica 
nanoparticles (MSNs),[13, 14] the research of MOSNs is still at an early stage. 
To date, much effort has been devoted to the synthesis of MOSNs with controlled particle size 
and dispersity. The first successful synthesis of monodispersed MOSNs with uniform sizes of ~ 20 
nm was reported by Kuroda and his coworkers, using bis-(triethoxysilyl)ethenylene in a basic 
aqueous solution containing cationic surfactants.[15] The higher hydrolysis resistance and enhanced 
hemocompatibility of MOSNs compared to traditional MSNs was demonstrated. An elegant 
synthesis of MOSNs was introduced by Huo group, where MOSNs with tunable particle diameters 
(30 - 500 nm) and 2D-hexganol or 3D-cubic ordered mesostructures were obtained.[16] In 2013, 
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Chen and co-workers prepared monodispersed hollow MOSNs (450 nm in particle size and 2.8 nm 
in pore diameter) via a strategy of organosilica coating and followed by a selective etching of pre-
formed silica core.[17] They firstly demonstrated the application of MOSNs for the delivery of 
Silibinin (molecular weight of 482 g/mol) into cancer cells. To our knowledge, the pore sizes of 
well dispersed MOSNs in literature reports are smaller than 3 nm, thus suitable only for the delivery 
of small molecular weight drugs into cells. It is still a challenge to synthesize MOSNs with small 
particle sizes but simultaneously larger pore sizes for the delivery of large molecular weight 
therapeutics such as proteins. 
Protein delivery has been regarded as a safe and direct strategy for manipulating cellular 
functions and the treatment of human diseases.[18] Due to the fragility and cell membrane 
impermeability of most therapeutic proteins, various nanomaterial based systems, including 
polymers,[19] liposomes,[20] and inorganic nanoparticles,[21] have been developed for safe and 
efficient protein delivery. Recent breakthroughs in the synthesis of silica nanoparticles including 
MSNs have led to a series of silica based delivery systems.[22-24] However, for cellular delivery 
application of proteins, the performance of nano-carriers with bare silica composition is limited thus 
post-functionalization is generally needed to improve the efficacy, which involves complicated 
processes and may cause particle aggregation or reduced biocompatibility.[13] Owing to the intrinsic 
hydrophobic property of MOSNs, we expect that MOSNs with large pores may be used directly 
without post-modification as a next-generation of nanocarrier system for the intracellular delivery 
of proteins. 
Herein, we report a facile synthesis of novel benzene bridged MOSNs in a water/toluene 
biphasic system. The MOSNs are well-dispersed with a uniform particle size of ~50 nm. Their pore 
size can be enlarged from 4.6 to 7.6 nm by adding isopropanol as a co-swelling agent. Compared to 
MOSNs with a pore size of 4.6 nm, MOSNs with a larger pore diameter of 7.6 nm show a higher 
loading amount of Ribonuclease A (RNase A) and sustained release profile, leading to excellent 
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cellular delivery performance of RNase A. To our knowledge, this is the first report on the synthesis 
of large-pore MOSNs as nano-carriers for successful intracellular delivery of therapeutic proteins. 
The MOSNs were synthesized in a biphasic reaction system with gentle stirring in aqueous 
phase (inset of Figure 1). The upper oil phase contained toluene and 1, 4-bis(triethoxysilyl)benzene 
(BTEB) as an organosilica source, while the lower aqueous phase included cetyltrimethylamine 
chloride (CTAC) as a structure directing agent and triethanolamine as a catalyst. In a separate 
experiment, isopropanol was added in the upper oil phase to enlarge pore size. After removing the 
surfactants by ethanol extraction method, the final products prepared with and without isopropanol 
were named as MOSNs-4.6 and MOSNs-7.6, respectively (the number denotes the pore size, see 
details in Materials and Methods, Supporting Information).  
Scanning electron microscope (SEM) images of MOSNs-4.6 and MOSNs-7.6 are shown in 
Figures 1a and 1b, respectively. Both particles have a spherical morphology with particles sizes of ~ 
50 nm. The porous nature can be directly seen, but more evident on MOSNs-7.6. The dynamic light 
scattering (DLS) measurements reveal that the average particle size of MOSNs-4.6 and MOSNs-7.6 
is 64 and 61 nm (Figures 1c, d), respectively. The polydispersity index (PDI) value is 0.08 for two 
samples, suggesting a uniform particle size distribution and excellent aqueous dispersity of MOSNs 
prepared in our biphasic approach.  
Transmission electron microscope (TEM) images of MOSNs prepared in the biphasic system 
are shown in Figure 2. Uniform and well dispersed nanoparticles with particle sizes of ~50 nm can 
be observed for both MOSNs-4.6 and MOSNs-7.6 under low magnifications (Figures 2a, b). At 
higher magnifications, TEM images show that MOSNs-4.6 has relatively smaller mesopores 
(Figure 2c), while MOSNs-7.6 exhibits larger mesopores (Figure 2d), in accordance with the SEM 
observations. The particle sizes measured from TEM images are slightly smaller than the DLS 
results, which is due to the surface hydration.[103] 
The nitrogen adsorption-desorption plots of two MOSNs show both type IV isotherms 
according to the IUPAC nomenclature (Figure 3). For the sample MOSNs-4.6, a small capillary 
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condensation step occurs in the P/P0 range of 0.4-0.6 (Figure 3a), corresponding to a pore size of 
~4.6 nm (inset of Figure 3a) with a relatively broad pore size distribution and small mesopore 
volume of ~ 0.18 cm3 g-1. When isopropanol is used in the synthesis (MOSNs-7.6), a capillary 
condensation step occurs at a higher P/P0 range from 0.7 to 0.8 with increased mesopore volume of 
~ 0.31 cm3 g-1. Accordingly, the pore size is calculated to be 7.6 nm (inset of Figure 3b). The 
Brunauer–Emmett–Teller (BET) surface area measured for sample MOSNs-4.6 and MOSNs-7.6 is 
688 and 941 m2 g-1, respectively, while the total pore volume is calculated to be 1.1 and 2.1 cm3 g-1, 
respectively. A steep capillary condensation step can be observed at a high relative pressure range 
(0.9 – 1.0), which can be attributed to the inter-particle packing voids of small sized MOSNs.[104] 
The small-angle X-ray scattering (SAXS) patterns of MOSNs-4.6 and MOSNs-7.6 reveal a 
broad scattering peak centered at q values of 0.52 and 0.61 nm-1 (Figure S1), respectively, 
indicating a disordered packing behavior of mesopores with a short range of periodicity.105 The 
corresponding d spacing of MOSNs-4.6 is calculated to be 10.3 nm, which can be attributed to the 
average distance of the closest neighboring mesopores.[106] This d spacing is around 2 times higher 
than that of typical mesoporous silica materials template by CTAC in a literature report (~ 5 nm), 
where a small pore size of 2.65 nm was obtained.[105] The enlarged d spacing and pore size provide 
evidences for the swelling of micelles in our synthesis. After the addition of isopropanol, MOSNs-
7.6 shows a further increased d spacing of 12.1 nm. The structural information of MOSNs-4.6 and 
MOSNs-7.6 is summarized in Table S1 for comparison. 
To understand the formation mechanism of large-pore MOSNs and the unique role of biphasic 
reaction system used in our synthesis, we conducted three control experiments. When keeping the 
other synthesis parameters the same as MOSNs-7.6, toluene was not added in control experiment I, 
neither toluene nor isopropanol was added in control experiment II, and using fast stirring to form 
emulsions in control experiment III. In all three control experiments where the biphasic condition is 
destroyed, only dense structures were obtained as evidenced by TEM, XRD and N2 sorption 
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measurements (Figures S2-S4), suggesting that the biphasic synthesis system is crucial in the 
preparation of large-pore MOSNs.  
The formation of mesoporous materials in dilute aqueous solutions generally follows a 
cooperative self-assembly (CSA) mechanism: negatively charged organosilica species (O-) interact 
with positively charged surfactants (S+) through electrostatic interaction to form silica/surfanctant 
composites (O-S+), which further self-assemble into mesostructures.[107] Compared to their 
inorganic counterparts, hydrolysed organosilica species have a lower charge density because of the 
electron donating effect of benzene groups, which destabilize the deprotonated silanols.[108] Hence, 
the interaction between O-S+ is weaker and energetically less favoured, which explains the much 
less reports on MOSNs compared to MSNs. On the other hand, further condensation of hydrolysed 
organosilica species may occur (O-O-), which forms cross-linked organosilica without defined 
mesostuctures. The competition between two interactions (O-S+ versus O-O-) has to be carefully 
manipulated in order to prepare MOSNs.  
In our biphasic synthesis system, BTEB molecules initially dissolved in the oil phase gradually 
diffuse into aqueous phase (Scheme 1A(a)), leading to lower concentration of hydrolysed 
organosilica species, which slows down the condensation and O-O- interaction and favors the O-S+ 
assembly (O-S+ > O-O-, Scheme 1A(b)) and eventually the formation of MOSNs (Scheme 1A(c)). In 
contrast, the initial concentration of hydrolysed organosilica species in our three control 
experiments is much higher compared to the biphasic system due to significantly increased contact 
area between BTEB and water molecules (Scheme 1B(d)). Consequently, the O-O- interaction 
dominates in the synthesis system (O-S+ < O-O-) (Scheme 1B(e)), resulting in dense organosilica 
without the formation of mesostructures (Scheme 1B(f)). 
The large pore sizes of MOSNs obtained in our biphasic system suggest that upper oil phase not 
only influences the assembly between surfactants and organosilica precursors, but also acts as a 
pore swelling agent. At first, the toluene molecules in the upper oil phase diffuse into the lower 
aqueous phase with the help of surfactants and locate in the core of the micelles to enlarge the 
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volume of hydrophobic core, leading to enlarged mesopores in the final products size (Scheme 
1A(a)). Upon the addition of isopropanol, it diffuses into the aqueous phase and penetrates into the 
interior of surfactant micelles, serving as a co-swelling agent for further pore expansion.[109-111] The 
diffusion of toluene and isopropanol into aqueous phase are evidenced by ultraviolet (UV) 
absorption (Figure S5) and Fourier transform infrared spectroscopy (FTIR, Figure S6), 
respectively.  
To demonstrate the potential application of large pore MOSNs as biomacromolecule delivery 
vehicles, RNase A is chosen as a model protein. The RNase A loading capacities of the two 
MOSNs with different pore size are firstly evaluated at pH 7.4 in phosphate buffered saline (PBS) 
solution (Figure 4 inset). It is found that MOSNs-7.6 possesses a loading capacity of 144.5 μg mg-1, 
which is almost two times as much as that of MOSNs-4.6 (74.6 μg mg-1). Such a significantly 
increased loading capacity is very likely to be attributed to the enlarged mesopores. Protein 
molecules can easily access into the large pore channels with reduced pore blocking, while the 
pores with 4.6 nm in diameter tend to be blocked due to the very close pore size and protein 
molecular size (~ 3.8 nm).[112, 113] Therefore, the protein molecules are presumably mainly adsorbed 
on the external surface of MOSNs-4.6, while both internal and external surface can be utilized in 
the case of MOSNs-7.6. This speculation is further evidence by the RNase A release profile (Figure 
4). It is noted that both of the two MOSNs show burst release in the first 10 h, where around 95% 
and 50% of protein molecules have been released from MOSNs-4.6 and MOSNs-7.6, respectively. 
This burst release is attributed to the protein molecules adsorbed on the external surface. Taking the 
difference in the loading capacity of two MOSNs into consideration,  the amount of protein released 
in the first 10 h are calculated roughly the same, indicating that very similar amount of protein 
molecules are adsorbed on the external surface for both NPs. An extended release over more than 
72 h is observed in the case of MOSNs-7.6, which is attributed to the strong hydrophobic 
interaction between organic-inorganic matrix and protein molecules and slow diffusion of protein 
molecules from pore channels.  
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The improved RNase A loading capacity and the sustained release profile of MOSNs-7.6 owing 
to the enlarged pore size strongly suggest the its potential suitability for efficient intracellular 
protein delivery applications. It is known that the efficient cellular uptake performance of nano-
carriers is also important to achieve high efficiency of therapeutic delivery applications. Firstly we 
investigated the cellular uptake performance of MOSNs-7.6 in a human breast adenocarcinoma cell 
line (MCF-7). Fluorescein isothiocyanate (FITC) was conjugated with (3-
Aminopropyl)triethoxysilane (APTES) before anchored onto MOSNs-7.6 (MOSNs-7.6-FITC) to 
generate green fluorescent signal (see Experimental section). The cell internalization was directly 
visualized by confocal laser scanning microscopy (CLSM). As shown in Figure S7, no green 
fluorescence can be observed in the cells without adding nanoparticles (Figure S7a), while MOSNs-
7.6-FITC was efficiently taken up by MCF-7 cells as evidenced by the strong green fluorescence 
observed in the cytoplasm (Figure S7b). To evaluate the cytotoxicity of MOSNs, the cell viability 
assay in the presence of MOSNs-4.6 and MOSNs-7.6 were conducted.  Figure S8 shows that after 
culturing for 24 h, 48 h and 72h, both of the two MOSNs show similar cytotoxicity with less than 
20 % of cell inhibition in the particle concentration of 40 μg/ml When the concentration increases to 
120 μg/ml, the cell viability remains above 75%. These results suggest the low cytotoxicity of 
MOSNs, which is similar to that of conventional mesoporous silica nanoparticles.[114]  
The intracellular delivery of RNase A was evaluated in MCF-7 cell line. The cell viability as a 
function of time after treatment of RNase A, MOSNs-7.6 and RNase A loaded MOSNs-7.6 
(MOSNs-7.6-RNase A) is shown in Figure 5. Pure RNase A at the dosage of 4 μg ml-1 shows 
negligible cytotoxicity at all of three time points due to its cell membrane impermeability. In 
contrast, the cell inhibition in the presence of MOSNs-7.6-RNase A exhibits a time dependent 
manner at the same protein dosage, where the cell death increases from 40% at 24 h to 56% at 48 h 
and finally 64% at 72 h. The significantly enhanced cytotoxicity of MOSNs-7.6-RNase A compared 
to pure RNase A should be attributed to the sufficient loading capacity, sustained release and 
efficient cell uptake of MOSNs-7.6 as demonstrated above. Compared to previous silica based 
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RNase A delivery systems using octadecyl modified solid silica nanoparticles (effective dosage 35 
μg/ml)[59] and octadecyl modified hollow silica NPs (effective dosage 8 μg/ml)[115], MOSNs-7.6 
exhibits a much lower effective RNase A dosage (4 μg/ml) to cancer cells without the need of any 
post functionalization, which is believed very advantageous for a convenient protein deliver system 
with lowered side effects. However, as expected, MOSNs-4.6-RNase A shows very limited cell 
inhibition ability of ~32% at three time points (Figure S9), which is mainly attributed to the rapid 
protein release profile. These results from cell studies further clearly suggested the promising 
potential of large pore MOSNs for efficient intracellular protein delivery applications.  
In summary, a facile biphase synthesis approach has been developed to prepare large pore (4.6-
7.6 nm) well dispersed MOSNs with uniform particle size of ~50 nm. The dual roles of the upper 
oil phase, including swelling mesopores and facilitating surfactant/organosilica assembly, are 
proposed.  With respect to biomedical application, MOSNs-7.6 show improved adsorption capacity 
more sustained release profile of RNase A than that of MOSNs-4.6.  The efficient cell uptake 
performance of MOSNs-7.6 is evidenced by CLSM image. RNase A loaded MOSNs-7.6 exhibits 
significantly enhanced cell inhibition compared to pure RNase A at a very low effective dosage of 4 
μg ml-1, Thus, the large pore MOSNs based protein delivery system is expected as promising 
platform for cellular delivery of various large biomacromolecules. 
 
Experimental Section  
Chemicals: Cetyltrimethylammonium chloride (CTAC) solution (25 wt % in H2O), 1, 4-
bis(triethoxysilyl)benzene (BTEB), triethanolamine (TEA) and Ribonuclease A (RNase A) were 
purchased from Sigma-Aldrich. Toluene, hydrochloric acid (HCl), iso-propanol, ethanol, methanol 
were received from ChemSupply Pty Ltd. All chemicals were used as received without purification. 
 
Preparation of mesoporous organosilica nanoparticles: Mesoporous organosilica nanoparticles 
(MOSNs) were achieved via a one-pot biphase synthesis system using cationic surfactant CTAC as 
a template, BTEB as a silica source, TEA as a catalyst and toluene as an emulsion agent. A typical 
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synthesis of MOSNs-4.6 was performed as follows. At first, 4 ml of 25 wt % CTAC solution and 
0.03 g of TEA were added to 6 ml of water and stirred gently at 40 °C in an oil bath under a 
magnetic stirring for 0.5 h. 5.95 mL of BTEB in toluene (20 v/v %) was then carefully added to the 
water-CTAC-TEA solution which was kept at 40 °C with gentle stirring for 72 h to obtain the 
products. The stirring rate was keep slow to ensure that only the lower aqueous phase was stirred 
while the upper oil phase was almost static. The products were collected by high speed 
centrifugation and washed for several times with ethanol to remove the residual reactants. Then, the 
collected products were extracted with HCl and methanol solution at 60.0 °C for 6 h for three times 
to remove the template, followed by drying in vacuum at room temperature overnight. For the 
synthesis of MOSNs-7.6, the procedures are similar to that of MOSNs-4.6, with the only difference 
that 0.16 ml of iso-propanol was added in the upper oil phase in the first step. For the three control 
experiments, the other synthesis conditions were kept the same, while toluene was not added in 
control experiment I, neither toluene nor isopropanol was added in control experiment II, and using 
fast stirring to form emulsions in control experiment III. 
 
Diffusion test of toluene and iso-propanol: The diffusion test of toluene was conducted in the 
biphasic system with conditions similar to that of MOSNs-4.6 and MOSNs-7.6, but without adding 
BTEB, while the diffusion of iso-propanol was conducted in the biphasic system with conditions 
similar to that of MOSNs-7.6 in the absence of BTEB. At certain time point, 200 μL of aqueous 
solution was collected. The presence of toluene and iso-propanol in aqueous solution was measured 
by FTIR and Nanodrop (WL = 261 nm) (NANODROP 1000 spectrophotometer (Thermo 
Scientific)), respectively.  
 
Characterizations: Transmission electron microscopy (TEM) images were obtained with a JEOL 
1010 operated at 100 kV. For TEM measurements, the samples were prepared by dispersing the 
powder samples in ethanol, after which they were dispersed and dried on carbon film on a Cu grid. 
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Dynamic light scattering (DLS) was carried out at 298 K using a Zetasizer Nano-ZS from Malvern 
Instruments. Small-angle X-ray scattering (SAXS) measurements were taken on a SAXess (Anton 
Parr). X-ray diffraction (Bruker, Germany) was conducted using Cu Kα radiation (30 kV, 35 mA). 
Nitrogen adsorption–desorption isotherms were measured at 77 K using a Micromeritics ASAP 
Tristar II 3020 system. The samples were degassed at 393 K overnight on a vacuum line. The pore 
size distribution curve was derived from the adsorption branch of the isotherms using the Barrett–
Joyner–Halanda (BJH) method. The Brunauer–Emmett–Teller (BET) method was utilized to 
calculate the specific surface areas. The total pore volume was calculated from the amount adsorbed 
at a maximum relative pressure (P/P0) of 0.99.  
 
RNase A loading and release of MOSNs: For the protein loading, RNase A was first dissolved in 
PBS (0.1 M, pH 7.4) to obtain a protein stock solution with a concentration of 2 mg ml-1. PBS 
buffer solution (0.75 ml) was added to 1.5 mg of the MOSNs in 2 ml capped vials. After the 
mixture was sonicated for 10 min, 0.75 ml of protein stock solution was added. The total volume 
and concentration of protein solution were 1.5 ml and 1 mg ml-1, respectively. The resulting mixture 
was shaking at 200 rpm at 10°C for 6 h followed by centrifugation. The amount of protein adsorbed 
to MOSNs was further quantified by measuring the absorbance of the supernatant at 280 nm. The 
amount of protein adsorbed was calculated by the concentration difference between before and after 
adsorption. 
For the protein release test, 3 mg of RNase A loaded MOSNs were immerged in 2 ml of PBS 
solution and gently shaken at 100 rpm at 37°C. At a predetermined time point, the solution was 
centrifuged and the supernatant was removed and replaced by the same amount of fresh PBS 
solution. The release amount of protein was quantified by UV-vis measurement. 
 
FTIC conjugation: FITC (3 mg) was reacted with 3-aminopropyltriethoxysilane (APTES, 20 μl) in 
ethanol (1 ml) under dark conditions for 24 h. Subsequently, MOSNs-7.6 (4 mg) was reacted with 
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FITC-APTES stock solution (1 ml) under dark conditions for 24 h. The FITC grafted particles were 
collected by centrifugation and washed with ethanol several times to remove the unreacted FITC-
APTES. Finally, the MOSNs-7.6-FITC was dried under vacuum at room temperature. 
 
Cell culture: Cell culture reagents were purchased from GIBCO Invitrogen Corporation/Life 
Technologies Life Sciences unless otherwise specified. MCF-7 (ATCC® HTB-22™) cells were 
maintained as monolayer cultures at 310 K and 5% CO2 in Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. The 
media were changed every two to three days and the cells were passaged by trypsinization.  
 
Cellular uptake assay: MCF-7 cells were seeded onto 24-mm glass coverslips in 6 well-plates at 
1×105 cells per well one day before the assay. MOSNs-7.6-FITC was incubated with cells at the 
concentration of 40 μg/ml for 6 h in serum-free medium. Afterwards, cells were washed with PBS 
twice and fixed with 4% paraformaldehyde in PBS for 30 minutes, following two more washes with 
PBS. Then, the coverslips were washed three times with PBS and mounted onto glass slides by 
fluoroshield with DAPI (Sigma). The uptake performance of nanoparticles was assessed using a 
confocal microscope  (LSM 710, ZEISS).  
 
Cytotoxicity assay: First, the cytotoxicity of MOSN-4.6 and MOSN-7.6 were determined by the 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) colorimetric assay. Cells 
(5×103 per well) were seeded in a flat-bottomed 96-well plate one day before the assay, and 
exposed to MOSNs-4.6 and MOSNs-7.6 with a series of concentrations (5, 10, 20, 40, 80, 120 
ug/ml) in serum containing medium. After incubation for 24, 48 and 72 hours respectively, the 
liquid was replaced with fresh medium containing 10 vol% MTT reagent (5 mg/ml in PBS), 
reacting with cells at 37 °C for 4 hours. Then, the medium was drained, and dimethyl sulfoxide 
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(DMSO) (50 μl) was added to dissolve the formazan crystal. Cell viability was determined by 
reading the absorbance at 540nm using a microplate reader.  
After that, the evaluation of RNase A delivery of MOSNs was also conducted. The procedures are 
the same as that of bare nanoparticles, except both nanoparticles was loaded with RNase A. The 
working concentration of RNase A used was 4 ug/ml. The cytotoxicity of RNase A was assessed by 
MTT assay at 24, 48 and 72 hours time points.  
 
 
Supporting Information  
Supporting Information is available from the Wiley Online Library or from the author. 
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Figure 1. SEM images of MOSNs-4.6 (a) and MOSNs-7.6 (b). Particle size distribution curves of 
MOSNs-4.6 (c) and MOSNs-7.6 (d). Inset is a digital image of the oil/water biphasic synthesis 
system of MOSNs-7.6.  
 
 
Figure 2. TEM images of MOSNs-4.6 (a, c) and MOSNs-7.6 (b, d).  
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Figure 3. N2 adsorption-desorption isotherms and pore size distribution curves (inset) calculated 
from the adsorption branches using the Barrett–Joyner–Halanda (BJH) method of MOSNs-4.6 (a) 
and MOSNs-7.6 (b). 
 
 
Scheme 1 Schematic representation of the formation mechanism of large-pore MOSNs in a biphasic 
system (A) and densely structured organosilicas without the biphasic synthesis (B). (a) A biphasic 
system with low initial concentration of organosilica species and swollen micelles; (b) assembly 
between organosilica species and CTA+ micelles; (c) mesostructure formation; (d) In a single phase 
system with high initial concentration of organosilica species; (e) organosilica condensation without 
surfanctant/organosilica assembly; (f) dense structure formation.  
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Figure 4. RNase A loading amount (inset) and cumulative release profile of MOSNs-4.6 and 
MOSNs-7.6 in PBS solution as a function of time. 
 
 
Figure 5. Evaluation of RNase A (4 μg/ml) delivery using MOSNs-7.6 on MCF-7 cell line after 24, 
48 and 72 h via a cytotoxicity assay. Data are presented as mean ±SD.  
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Figure S1. SAXS patterns of MOSNs-4.6 and MOSNs-7.6. 
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Figure S2. TEM image (a), XRD pattern (b), N2 adsorption-sorption isotherms (c) and pore size 
distribution (d) of MOSNs obtained in isopropanol/water system (without adding toluene as oil 
phase). The peak at ~20 nm in pore size distribution curve should be attributed to the inter-particle 
packing voids (control experiment I). 
 
 
Figure S3. TEM (inset) and corresponding XRD pattern of MOSNs obtained without toluene and 
iso-propoanol (control experiment II). 
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Figure S4. TEM (inset) and corresponding XRD pattern of MOSNs obtained by fast stirring in 
toluene/water/isopropanol system (control experiment III). 
 
 
Figure S5. UV absorbance measurement (wavelength: 261 nm) of toluene diffused into aqueous 
phase as a function of time using toluene or toluene/isopropanol mixture as the upper oil phase. 
 
 
Figure S6. FTIR spectra of isopropanol diffused into aqueous phase as a function of time with 
toluene/isopropanol mixture as the upper oil phase. (a) 0h, (b) 0.5h, (c) 1h, (d) 2h. 
 
The UV absorption results (Figure S5) show that the amount of toluene diffused into aqueous 
phase and the diffusion rate in the absence or presence of iso-propanol are quite similar. This 
diffusion process undergoes relatively slow kinetics with a time period of ~8 h, as evidenced by the 
saturation time of 8 h. This slow diffusion rate should be attributed to the hydrophobic property of 
toluene. In contrast, the diffusion rate of iso-propanol from oil phase to aqueous is much faster 
than that of toluene, because of its highly hydrophilic property. This diffusion is finished within 0.5 
h, since the intensity of three characteristic peaks (947 nm-1 δ(CH) , 1027 nm-1 ν(C-C) and 1163 
nm-1 ν(C-O)) of iso-propanol have no obvious difference (Figure S6). 
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Figure S7. Confocal microscopy images of MCF-7 cells (a) without adding nanoparticles and (b) 
with treatment of MOSNs-7.6-FITC (green) with 40 μg/mL in 6 h. Nuclei are stained with DAPI 
(blue). Scale bar: 10 μm. 
 
 
Figure S8. Cytotoxicity of MOSNs-4.6 (A) and MOSNs-7.6 (B) as a function of particle 
concentration in MCF-7 cell line after 24, 48 and 72 h. 
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Figure S9. Evaluation of RNase A (4 μg/ml) delivery using MOSNs-4.6 in MCF-7 cell line after 24, 
48 and 72 h via a cytotoxicity assay. Data are presented as mean ±SD. 
 
Table S1 Structural properties of MOSNs. 
Sample Name 
Pore Size 
(nm) 
Vp (cm3 g−1) 
SBET (m2 g-
1) 
d spacing 
(nm) 
MOSNs-4.6 4.6 1.1 688 10.3 
MOSNs-7.6 7.6 2.1 941 12.1 
Note: Vp: total pore volume; SBET: BET surface area. 
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Chapter 6. Conclusions and Recommendations 
6.1 Conclusions 
This thesis aims at synthesizing different type of porous silica nanoparticles via 
cooperative self assembly mechanism. Silica vesicles, SBA-15 rods and mesoporous 
organosilica nanoparticles with small particle size, large pore size, good dispersity and 
tuneable structures have been prepared for effective intracellular drug delivery. In addition, 
the fundamental correlation between the particle structure parameters and therapy efficacy 
was established based on drug adsorption capacity and cell uptake efficiency. Our findings 
have demonstrated that small sized silica vesicles with reduced aggregation can 
effectively inhibit cancer cell growth because of high drug loading capacity and cellular 
uptake efficiency. Since the cellular uptake efficiency plays an important role in therapeutic 
delivery, we successfully prepared small sized SBA-15 rods, showing enhanced cellular 
uptake efficiency as well as higher protein loading capacity compared to large ones. To 
achieve a sustained cargo release, small sized well dispersed mesoporous organosilica 
nanoparticles was fabricated. Our results show that a sufficiently large pore size is 
essential for a high loading capacity and sustained release, resulting in excellent 
therapeutic efficacy in vitro.   
Furthermore, the detailed formation mechanisms for each type of nanoparticle were 
proposed, providing guideline to synthesis self-assembled silica nanoparticles with better 
structures and enhance performance in therapeutic delivery. 
 
1. A facile synthesis of silica vesicles (SVs) of ~30 nm with reduced aggregation using 
binary surfactant P123 and L121 and mixed silica source of TEOS and TPOS have been 
developed. The FTIR results as a function of reaction time evidence that the reduced inter-
particle aggregation is attributed to the incompletely hydrolysed TPOS, where the 
presence of propoxy group on the particle surface can effectively prevent the inter-particle 
cross-linking. Furthermore, in order to demonstrate the drug delivery application, SiPC 
were chosen as a model drug and loaded in the SVs.  They shows very high drug loading 
capacity of ~40%, which is attributed to the large pore volume as a result of the hollow 
structure. Cell studies of SiPC loaded SVs shows efficient intracellular delivery of drug as 
directly visualized by confocal images. According to the cytotioxicity assay, the efficient 
cell inhibition in the presence of SiPC loaded SVs further confirms the potential application 
of our materials as effitient drug delivery vehicles. 
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2. Since the small sized spherical silica nanoparticles are favourable in terms of cell 
uptake, we have developed a facile synthesis of small sized SBA-15 nanoparticles with 
rodlike morphology and understand their cell uptake perfoomance. By finely tune the 
synthesis pH in a narrow range from 3.40-3.88, SBA-15 rods of 80-200 nm in length, ∼ 30 
nm in width and pore size of 8.3 nm are obtained.  We propose that the formation the 
small sized rods is associated to the structural evolution from rodlike to vesicular structure, 
which can be obtained by a small increase of pH to 3.98. Furthermore, SBA-15 rods 
prepared in this study demonstrate higher adsorption capacity towards large protein 
molecules such as bovine serum albumin and lysozyme, and enhanced cellular uptake 
efficiency in human osteosarcoma cancer cells compared to traditional SBA-15 with 
relatively larger particle sizes and MCM-41 with smaller pore sizes. 
 
3. Based on our previous results, sufficiently large pore size, small particles size and high 
dispersity are crucial factors for high performance of nanocarriers for intracellular 
therapeutics delivery. In order to further enhance the cargo loading capacity and release 
profile, we designed mesoporous organosilica nanoparticles (MOSNs) by incorporating 
organic functional groups, which possess higher affinity towards hydrophobic therapeutics 
though hydrophobic interaction and/or π-π stacking. In this chapter, a facile biphase 
synthesis approach has been developed to prepare large pore (4.6-7.6 nm) well dispersed 
MOSNs with uniform particle size of ~50 nm. The dual roles of the upper oil phase, 
including swelling mesopores and facilitating surfactant/organosilica assembly, are 
proposed.  With respect to biomedical application, MOSNs-7.6 show improved adsorption 
capacity and more sustained release profile of RNase A than that of MOSNs-4.6.  The 
efficient cell uptake performance of MOSNs-7.6 is evidenced by CLSM image. RNase A 
loaded MOSNs-7.6 exhibits significantly enhanced cell inhibition compared to pure RNase 
A at a very low effective dosage of 4 μg ml-1, Thus, the large pore MOSNs based protein 
delivery system is expected as promising platform for cellular delivery of various large 
biomacromolecules. 
 
In summary, self assembled nanoporous silica nanoparticles are promising nanocarriers 
for therapeutic delivery for cancer therapy, owing to their large pore size, high pore volume 
and porous structure. Small sized silica vesicles with reduced aggregation show efficient 
cell inhibition after loading of anti-cancer drug. To expand the application of therapeutic 
delivery to large bimolecules, we synthesized SBA-15 rods with small size and large 
pores, showing enhanced protein loading capacity and superior cell uptake efficiency. To 
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further improve the protein delivery performance, we incorporate organic functional groups 
in the silica framework to achieve a high loading capacity and sustained release profile, 
owing to the hydrophobic interaction between guest molecules and nanoparticle surface. 
Therefore, a significantly enhanced cell inhibition was obtained based on cell studies. Our 
research points a clear direction for the synthesis of functional nanoporous silica materials 
for efficient intracellular therapeutic delivery. 
 
6.2 Recommendations and future work 
The following recommendations are made for the future work. 
1. The size of silica nanoparticles used in biomedicine should be carefully controlled, too 
big to be taken by cell while too small to be controlled in the body circular system. 
 
2. Considering the in vivo use of silica materials, their biodegradability is one of the most 
important properties for the clinical applications. Therefore, to further show the suitability of 
our silica based nanocarriers for therapeutic delivery, their biodegradability should be 
systematically studied.  
 
3 In order to minimize the side effects of therapeutic agents, nanocarriers should possess 
two important properties: cancer cell targeting ability and “zero” pre-mature release. As a 
result, different types of stimuli-responsive agents, such as polymers and metal oxide, can 
be attached on the surface of nanoparticles to serve as “gate keeper” to prevent the 
premature release. Those “gate keeper” should be removable in a certain environment, 
such as decreased pH or increased redox concentration, triggering a burst drug release. 
Targeting property can be achieved by conjugating agents that has strong affinity to 
cancer cells, such as folic acid and aptamer, to enhance the accumulation of drug-
nanoparticles composite on cancer cells while retain the healthy condition for normal cells. 
 
4. With respect the materials synthesis, a big issue is that current synthesis approached 
are very expensive and difficult to scale up. This dramatically hinders the use of silica 
materials in industry. A great challenge for us is to develop a very cheap, convenient 
scalable and highly reproducible approach to synthesis high quality nanomaterials suitable 
for commercialization.  
 
 
 
